Moosavi-Kohnehsari Reyhaneh Sadat, Jafari-Sohi Mahnaz, Piri-Gharaghie Tohid, Tolou-Shikhzadeh-Yazdi Shakiba, Aghassizadeh-Sherbaf Mona, Hosseinzadeh Romina
Department of Biology, Faculty of Basic Sciences, East Tehran Branch, Islamic Azad University, Tehran, Iran.
Department of Microbiology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.
Poult Sci. 2025 Feb;104(2):104789. doi: 10.1016/j.psj.2025.104789. Epub 2025 Jan 7.
A major health and financial burden in the chicken sector is salmonella infection. It is difficult to create an oral vaccination that can provide strong intestinal mucosal immunity in birds, particularly cross-protection against several Salmonella serotypes. As a result, the poultry industry needs a powerful oral vaccination platform that uses live bacterial vectors to prevent various Salmonella serotypes. The genetically engineered L. lactis was given orally to birds as a vaccine after a multi-epitope vector was created using a reverse vaccinology technique. After the plasmid was digested, the target group produced a 72 kDa protein called multi-epitop. Birds that received the L. lactis/pNZ8121-Multi epitope vaccination showed increased levels of interferon (IFN-γ) and NFkB1α, increased transcription rates of cytokines, and a significant presence of IgY antibodies specific to the multi epitope gene in their serum. Salmonella infection is a severe health and economic burden in the poultry industry, according to spleen sections from the L. lactis/pNZ8121-Multi epitope. Developing an oral vaccine that can provide birds robust intestinal mucosal immunity-specifically, cross-protection against many Salmonella serotypes-is challenging. The results provide a fresh method for creating new immunological candidate multi-epitome genes by using the food-grade, non-pathogenic Lactococcus lactis as a protein cell factory. This method provides a unique technique to assess the long-term sustainability, cost, safety, and usefulness of experimental pharmaceutical products.
沙门氏菌感染是养鸡业的一项重大健康和经济负担。很难研发出一种能在禽类中提供强大肠道黏膜免疫的口服疫苗，尤其是针对多种沙门氏菌血清型的交叉保护。因此，家禽业需要一个强大的口服疫苗平台，利用活细菌载体来预防各种沙门氏菌血清型。在使用反向疫苗学技术创建多表位载体后，将基因工程改造的乳酸乳球菌作为疫苗口服给禽类。质粒消化后，目标组产生了一种名为多表位的72 kDa蛋白质。接受乳酸乳球菌/pNZ8121-多表位疫苗接种的禽类血清中干扰素（IFN-γ）和NFkB1α水平升高，细胞因子转录率提高，并且存在针对多表位基因的特异性IgY抗体。根据乳酸乳球菌/pNZ8121-多表位的脾脏切片结果，沙门氏菌感染是家禽业严重的健康和经济负担。研发一种能为禽类提供强大肠道黏膜免疫——特别是针对多种沙门氏菌血清型的交叉保护——的口服疫苗具有挑战性。这些结果提供了一种新方法，即利用食品级、无致病性的乳酸乳球菌作为蛋白质细胞工厂来创建新的免疫候选多表位基因。这种方法提供了一种独特的技术，用于评估实验性药品的长期可持续性、成本、安全性和实用性。
